论文部分内容阅读
１５３Ｓｍ－乙二胺四甲基膦酸（ＥＤＴＭＰ）在骨转移瘤病人的体内药代动力学表明：静脉注射后１小时，药物已基本从血中清除，８小时后尿液中几乎无放射性．第一次病人静脉内注射７４０ＭＢｑ１５３Ｓｍ－ＥＤＴＭＰ，测得１３６例病人的尿排泄率为３７．４２％±１６．４０％，骨摄取率为６２．７８％±１６．０８％．根据骨摄取率和红骨髓吸收剂量，再计算第二次应补足的剂量，可以避免骨髓不必要的损伤．还可判断转移灶的吸收剂量，达到最佳治疗效果．
In vivo pharmacokinetics of 153Sm-ethylenediaminetetramethylphosphonic acid (EDTMP) in patients with bone metastases showed that the drug had been substantially cleared from the blood one hour after intravenous injection and almost no radioactivity in urine after 8 hours. The first patient received 740MBq153Sm-EDTMP by intravenous injection. The urinary excretion rate of 136 patients was 37.42% ± 16.40% and the bone uptake rate was 62.78% ± 16.08%. According to the bone uptake rate and red bone marrow absorption dose, and then calculate the second dose should make up, to avoid unnecessary bone marrow damage. Can also determine the dose absorbed metastasis, to achieve the best therapeutic effect.